• Innocan Pharma Ltd. filed its MD&A for the three months ended March 31, 2026; revenue fell 17.7% to US$6.47 million.
• Net loss widened to US$886,000 from US$229,000; operating loss was US$786,000.
• Cash was US$6.63 million; working capital was US$9.19 million; operating cash flow was negative at US$506,000.
• Issued a secured debenture to Tamar Innovest for US$450,000 at 10%; a second US$200,000 debenture was issued post-quarter.
• Plans call for LPT-CBD scale-up over about one year, then GLP single-injection safety work over 6-8 months before an IND submission.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innocan Pharma Ltd. published the original content used to generate this news brief on May 27, 2026, and is solely responsible for the information contained therein.